Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice #
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Steatosis in the liver is a common feature of obesity and type 2 diabetes and the precursor to the development of nonalcoholic steatohepatitis (NASH), cirrhosis, and liver failure. It has been shown previously that inhibiting glycosphingolipid (GSL) synthesis increases insulin sensitivity and lowers glucose levels in diabetic rodent models. Here we demonstrate that inhibiting GSL synthesis in ob/ob mice not only improved glucose homeostasis but also markedly reduced the development of hepatic steatosis. The ob/ob mice were treated for 7 weeks with a specific inhibitor of glucosylceramide synthase, the initial enzyme involved in the synthesis of GSLs. Besides lowering glucose and hemoglobin A1c (HbA1c) levels, drug treatment also significantly reduced the liver/body weight ratio, decreased the accumulation of triglycerides, and improved several markers of liver pathology. Drug treatment reduced liver glucosylceramide (GL1) levels in the ob/ob mouse. Treatment also reduced the expression of several genes associated with hepatic steatosis, including those involved in lipogenesis, gluconeogenesis, and inflammation. In addition, inhibiting GSL synthesis in diet-induced obese mice both prevented the development of steatosis and partially reversed preexisting steatosis. Conclusion: These data indicate that inhibiting GSL synthesis ameliorates the liver pathology associated with obesity and diabetes, and may represent a novel strategy for treating fatty liver disease and NASH. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Enhanced insulin sensitivity in mice lacking ganglioside GM3
Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., Kono, M., Tsuji, S., Daniotti, J. L., Werth, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0635898100 · Cited by 531
Savage, D. B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27300 · Cited by 447
Choi, C. S., Savage, D. B., Kulkarni, A., Yu, X. X., Liu, Z.-X., Morino, K., Kim, S., Distefano, A., Samuel, V. T., Neschen, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704213200 · Cited by 383
Ganglioside GM3 Participates in the Pathological Conditions of Insulin Resistance
Tagami, S., Inokuchi, J.-I., Kabayama, K., Yoshimura, H., Kitamura, F., Uemura, S., Ogawa, C., Ishii, A., Saito, M., Ohtsuka, Y., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m103705200 · Cited by 355
Kabayama, K. (2004) · Glycobiology · doi:10.1093/glycob/cwh135 · Cited by 155
Cited by
A Ceramide-Centric View of Insulin Resistance
Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 610
Stienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology · doi:10.1002/hep.23337 · Cited by 452
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Ceramides as modulators of cellular and whole-body metabolism
Bikman, B. T., & Summers, S. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57144 · Cited by 419
Ceramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Metadata
- Authors
- Zhao, H., Przybylska, M., Wu, I.-H., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P., Copeland, D., Arbeeny, C., Shayman, J. A., Aerts, J. M., Jiang, C., Cheng, S. H., & Yew, N. S.
- Venue
- Hepatology
- Published
- 2009-07
- Volume
- 50
- Issue
- 1
- Pages
- 85-93
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2136423962
- Cited by
- 88
- References
- 9
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice #. https://app.cochat.ai/papers/10.1002/hep.22970
- The paper
- Zhao, H., Przybylska, M., Wu, I.-H., Zhang, J., Maniatis, P., Pacheco, J., Piepenhagen, P., Copeland, D., Arbeeny, C., Shayman, J. A., Aerts, J. M., Jiang, C., Cheng, S. H., & Yew, N. S. (2009). Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice #. Hepatology. https://doi.org/10.1002/hep.22970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.